{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:29:28Z","timestamp":1782952168906,"version":"3.54.5"},"reference-count":108,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T00:00:00Z","timestamp":1743206400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>In the recent 2024 ESMO guidelines, the combination of venetoclax and ibrutinib was listed as one of the first-line treatment options for CLL patients. These drugs were first-in-class medicines that revolutionized CLL management, extending patients\u2019 overall survival even in cases refractory to immunochemotherapy. However, since the approval of both compounds, more and more Bruton Tyrosine Kinase inhibitors (BTKis) and B-cell lymphoma 2 inhibitors (BCL2is) have been discovered. Their efficacy and safety are the reasons for their use in monotherapy among both treatment-na\u00efve and relapsed patients with CLL. Currently, several ongoing clinical trials are investigating the rationale for the combination of BCL2is and BTKis. In this review, we discuss the recent advancements in the field of co-therapy with BTKis and BCL2is.<\/jats:p>","DOI":"10.3390\/ijms26073193","type":"journal-article","created":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T03:25:02Z","timestamp":1743391502000},"page":"3193","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Double Strike in Chronic Lymphocytic Leukemia\u2014The Combination of BTK and BCL2 Inhibitors in Actual and Future Clinical Practice"],"prefix":"10.3390","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-1404-7544","authenticated-orcid":false,"given":"Przemyslaw","family":"Zygmunciak","sequence":"first","affiliation":[{"name":"Faculty of Medicine, Warsaw Medical University, 02-091 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-1596-2232","authenticated-orcid":false,"given":"Hanna","family":"Dancewicz","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Warsaw Medical University, 02-091 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"Str\u00f3\u017cna","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Warsaw Medical University, 02-091 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-6989-3062","authenticated-orcid":false,"given":"Olga","family":"B\u0142a\u017cowska","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Warsaw Medical University, 02-091 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-3082-5254","authenticated-orcid":false,"given":"Krzysztof","family":"Bieli\u0144ski","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Warsaw Medical University, 02-091 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3411-6357","authenticated-orcid":false,"given":"Tadeusz","family":"Robak","sequence":"additional","affiliation":[{"name":"Department of Hematology, Medical University of Lodz, 93-510 Lodz, Poland"},{"name":"Department of General Hematology, Copernicus Memorial Hospital, 93-510 Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bartosz","family":"Pu\u0142a","sequence":"additional","affiliation":[{"name":"Department of Hematology, Medical University of Lodz, 93-510 Lodz, Poland"},{"name":"Department of General Hematology, Copernicus Memorial Hospital, 93-510 Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,3,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"3755","DOI":"10.1002\/cncr.29049","article-title":"The Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer Institute","volume":"120","author":"Cronin","year":"2014","journal-title":"Cancer"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1080\/10428190600555819","article-title":"Sex differences in incidence and outcome of chronic lymphocytic leukemia patients","volume":"47","author":"Molica","year":"2006","journal-title":"Leuk. Lymphoma"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1182\/blood.V94.2.448","article-title":"Clinical characteristics and outcome of young chronic lymphocytic leukemia patients: A single institution study of 204 cases","volume":"94","author":"Mauro","year":"1999","journal-title":"Blood"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.annonc.2020.09.019","article-title":"Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Eichhorst","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.annonc.2024.06.016","article-title":"ESMO Clinical Practice Guideline interim update on new targeted therapies in the first line and at relapse of chronic lymphocytic leukaemia","volume":"35","author":"Eichhorst","year":"2024","journal-title":"Ann. Oncol."},{"key":"ref_6","unstructured":"(2025, March 24). BREYANZI (Lisocabtagene Maraleucel), Available online: https:\/\/www.fda.gov\/vaccines-blood-biologics\/cellular-gene-therapy-products\/breyanzi-lisocabtagene-maraleucel."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1158\/1078-0432.CCR-23-1272","article-title":"FDA Approval Summary: Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma","volume":"30","author":"Telaraja","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa2300696","article-title":"Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia","volume":"389","author":"Mato","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"TPS7582","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS7582","article-title":"BRUIN CLL-321: A phase 3 open-label, randomized study of pirtobrutinib versus investigator\u2019s choice of idelalisib plus rituximab or bendamustine plus rituximab in BTK inhibitor pretreated chronic lymphocytic leukemia\/small lymphocytic lymphoma","volume":"41","author":"Follows","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/S0140-6736(23)01052-8","article-title":"Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): A multicentre, open-label, single-arm, phase 1-2 study","volume":"402","author":"Siddiqi","year":"2023","journal-title":"Lancet"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Zygmunciak, P., Robak, T., and Pu\u0142a, B. (2024). Treatment of Double-Refractory Chronic Lymphocytic Leukemia-An Unmet Clinical Need. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25031589"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/s41375-020-01072-6","article-title":"Inhibitors targeting Bruton\u2019s tyrosine kinase in cancers: Drug development advances","volume":"35","author":"Wen","year":"2021","journal-title":"Leukemia"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"6287","DOI":"10.1182\/blood-2011-01-328484","article-title":"Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765","volume":"117","author":"Herman","year":"2011","journal-title":"Blood"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1002\/ajh.26367","article-title":"Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures","volume":"96","author":"Hallek","year":"2021","journal-title":"Am. J. Hematol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1182\/blood.2023023659","article-title":"Mutational profile in previously treated patients with chronic lymphocytic leukemia progression on acalabrutinib or ibrutinib","volume":"144","author":"Woyach","year":"2024","journal-title":"Blood"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s11523-021-00857-8","article-title":"Bruton Tyrosine Kinase Inhibitors in B-Cell Malignancies: Their Use and Differential Features","volume":"17","author":"Shirley","year":"2022","journal-title":"Target. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Ahn, I.E., and Brown, J.R. (2021). Targeting Bruton\u2019s Tyrosine Kinase in CLL. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.687458"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Montoya, S., and Thompson, M.C. (2023). Non-Covalent Bruton\u2019s Tyrosine Kinase Inhibitors in the Treatment of Chronic Lymphocytic Leukemia. Cancers, 15.","DOI":"10.3390\/cancers15143648"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1200\/JCO.2012.42.7906","article-title":"Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed\/refractory B-cell malignancies","volume":"31","author":"Advani","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1400376","article-title":"Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia","volume":"371","author":"Byrd","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1002\/ajh.25638","article-title":"Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma","volume":"94","author":"Munir","year":"2019","journal-title":"Am. J. Hematol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"S179","DOI":"10.1016\/S2152-2650(24)00565-2","article-title":"Final Analysis of the RESONATE-2 Study: Up to 10 Years of Follow-Up of First-Line Ibrutinib Treatment in Patients with Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma","volume":"24","author":"Burger","year":"2024","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1056\/NEJMc2005943","article-title":"Ibrutinib for Chronic Lymphocytic Leukemia with TP53 Alterations","volume":"383","author":"Ahn","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1182\/blood-2016-05-712828","article-title":"The risk of atrial fibrillation with ibrutinib use: A systematic review and meta-analysis","volume":"128","author":"Leong","year":"2016","journal-title":"Blood"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1182\/blood.2019000840","article-title":"Hypertension and incident cardiovascular events following ibrutinib initiation","volume":"134","author":"Dickerson","year":"2019","journal-title":"Blood"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1016\/j.jacc.2019.07.056","article-title":"Cardiovascular Toxicities Associated with Ibrutinib","volume":"74","author":"Salem","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"130","DOI":"10.5603\/ahp.100523","article-title":"Expert opinion on use of acalabrutinib for chronic lymphocytic leukemia treatment","volume":"55","author":"Jamroziak","year":"2024","journal-title":"Acta Haematol. Pol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1509981","article-title":"Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia","volume":"374","author":"Byrd","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1182\/blood.2018884940","article-title":"Acalabrutinib monotherapy in patients with relapsed\/refractory chronic lymphocytic leukemia: Updated phase 2 results","volume":"135","author":"Byrd","year":"2020","journal-title":"Blood"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e187","DOI":"10.1111\/ajco.13179","article-title":"Ibrutinib-related atrial fibrillation: A single center Australian experience","volume":"15","author":"Ezad","year":"2019","journal-title":"Asia Pac. J. Clin. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.3324\/haematol.2020.272500","article-title":"Phase II study of acalabrutinib in ibrutinib-intolerant patients with relapsed\/refractory chronic lymphocytic leukemia","volume":"106","author":"Rogers","year":"2021","journal-title":"Haematologica"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1182\/blood.2022018818","article-title":"Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial","volume":"142","author":"Seymour","year":"2023","journal-title":"Blood"},{"key":"ref_33","first-page":"53","article-title":"Zanubrutinib: A novel therapeutic option for the treatment of B-cell neoplasms","volume":"54","author":"Majeranowski","year":"2023","journal-title":"Acta Haematol. Pol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s13045-020-00884-4","article-title":"Treatment of relapsed\/refractory chronic lymphocytic leukemia\/small lymphocytic lymphoma with the BTK inhibitor zanubrutinib: Phase 2, single-arm, multicenter study","volume":"13","author":"Xu","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJMoa2211582","article-title":"Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia","volume":"388","author":"Brown","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1080\/17460441.2023.2236547","article-title":"The preclinical discovery and development of orelabrutinib as a novel treatment option for B-cell lymphoid malignancies","volume":"18","author":"Robak","year":"2023","journal-title":"Expert. Opin. Drug Discov."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1002\/ajh.26826","article-title":"Orelabrutinib in relapsed or refractory chronic lymphocytic leukemia\/small lymphocytic lymphoma patients: Multi-center, single-arm, open-label, phase 2 study","volume":"98","author":"Xu","year":"2023","journal-title":"Am. J. Hematol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"e295","DOI":"10.3324\/haematol.2015.140806","article-title":"Phase I study of single-agent CC-292, a highly selective Bruton\u2019s tyrosine kinase inhibitor, in relapsed\/refractory chronic lymphocytic leukemia","volume":"101","author":"Brown","year":"2016","journal-title":"Haematologica"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1182\/blood-2015-08-664086","article-title":"A phase 1 clinical trial of the selective BTK inhibitor ONO\/GS-4059 in relapsed and refractory mature B-cell malignancies","volume":"127","author":"Walter","year":"2016","journal-title":"Blood"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s12185-022-03514-6","article-title":"Long-term safety profile of tirabrutinib: Final results of a Japanese Phase I study in patients with relapsed or refractory B-cell malignancies","volume":"117","author":"Munakata","year":"2023","journal-title":"Int. J. Hematol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/S0140-6736(21)00224-5","article-title":"Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): A phase 1\/2 study","volume":"397","author":"Mato","year":"2021","journal-title":"Lancet"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1182\/bloodadvances.2022008447","article-title":"Pirtobrutinib targets BTK C481S in ibrutinib-resistant CLL but second-site BTK mutations lead to resistance","volume":"7","author":"Naeem","year":"2023","journal-title":"Blood Adv."},{"key":"ref_43","first-page":"92","article-title":"Pirtobrutinib monotherapy in Bruton tyrosine kinase inhibitor-intolerant patients with B-cell malignancies: Results of the phase I\/II BRUIN trial","volume":"110","author":"Shah","year":"2025","journal-title":"Haematologica"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1097\/01.HS9.0000845612.25766.0c","article-title":"P682: Nemtabrutinib (MK-1026), A Non-Covalent Inhibitor of Wild-Type and C481S Mutated Bruton Tyrosine Kinase for B-Cell Malignancies: Efficacy and Safety of the Phase 2 Dose-Expansion Bellwave-001 Study","volume":"6","author":"Woyach","year":"2022","journal-title":"HemaSphere"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1158\/2159-8290.CD-23-0670","article-title":"First-in-Human Study of the Reversible BTK Inhibitor Nemtabrutinib in Patients with Relapsed\/Refractory Chronic Lymphocytic Leukemia and B-Cell Non-Hodgkin Lymphoma","volume":"14","author":"Woyach","year":"2024","journal-title":"Cancer Discov."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1875.2","DOI":"10.1182\/blood-2024-198731","article-title":"Nemtabrutinib Versus Ibrutinib or Acalabrutinib for Untreated Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma: The Phase 3, Open-Label, Randomized Bellwave-011 Study","volume":"144","author":"Tadmor","year":"2024","journal-title":"Blood"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"984","DOI":"10.3324\/haematol.2021.280061","article-title":"Phase Ib dose-escalation study of the selective, non-covalent, reversible Bruton\u2019s tyrosine kinase inhibitor vecabrutinib in B-cell malignancies","volume":"107","author":"Allan","year":"2022","journal-title":"Haematologica"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"13023","DOI":"10.18632\/oncotarget.24310","article-title":"First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL","volume":"9","author":"Byrd","year":"2018","journal-title":"Oncotarget"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1002\/ajh.26888","article-title":"DTRMWXHS-12, a novel Bruton tyrosine kinase inhibitor, in combination with everolimus and pomalidomide in patients with relapsed\/refractory lymphomas: An open-label, multicenter, phase 1a\/1b study","volume":"98","author":"Huntington","year":"2023","journal-title":"Am. J. Hematol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"5953","DOI":"10.1182\/blood-2023-181151","article-title":"A Phase 1a\/b Trial of Luxeptinib (CG-806) in Patients with Relapsed\/Refractory B-Cell Malignancies or Acute Myeloid Leukemia and Evaluation of New G3 Formulation","volume":"142","author":"Goldberg","year":"2023","journal-title":"Blood"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.cell.2016.02.026","article-title":"BOK Is a Non-canonical BCL-2 Family Effector of Apoptosis Regulated by ER-Associated Degradation","volume":"165","author":"Llambi","year":"2016","journal-title":"Cell"},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Lasica, M., and Anderson, M.A. (2021). Review of Venetoclax in CLL, AML and Multiple Myeloma. J. Pers. Med., 11.","DOI":"10.3390\/jpm11060463"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"13944","DOI":"10.1073\/pnas.0506654102","article-title":"miR-15 and miR-16 induce apoptosis by targeting BCL2","volume":"102","author":"Cimmino","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.trecan.2016.07.001","article-title":"Targeting BCL-2-like Proteins to Kill Cancer Cells","volume":"2","author":"Cory","year":"2016","journal-title":"Trends Cancer"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S1470-2045(10)70261-8","article-title":"Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: A phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity","volume":"11","author":"Wilson","year":"2010","journal-title":"Lancet Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Josefsson, E.C., Vainchenker, W., and James, C. (2020). Regulation of Platelet Production and Life Span: Role of Bcl-xL and Potential Implications for Human Platelet Diseases. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21207591"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1513257","article-title":"Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia","volume":"374","author":"Roberts","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"e1593","DOI":"10.1038\/cddis.2014.525","article-title":"MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K\/AKT\/mTOR activation in lymphoid malignancies","volume":"6","author":"Choudhary","year":"2015","journal-title":"Cell Death Dis."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"94","DOI":"10.5603\/AHP.a2022.0013","article-title":"Chronic lymphocytic leukemia following venetoclax treatment failure","volume":"53","year":"2022","journal-title":"Acta Haematol. Pol."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Tahir, S.K., Smith, M.L., Hessler, P., Rapp, L.R., Idler, K.B., Park, C.H., Leverson, J.D., and Lam, L.T. (2017). Potential mechanisms of resistance to venetoclax and strategies to circumvent it. BMC Cancer, 17.","DOI":"10.1186\/s12885-017-3383-5"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"3362","DOI":"10.1182\/blood-2017-01-763003","article-title":"Clinicopathological features and outcomes of progression of CLL on the BCL2 inhibitor venetoclax","volume":"129","author":"Anderson","year":"2017","journal-title":"Blood"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1158\/2159-8290.CD-18-1119","article-title":"Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia","volume":"9","author":"Blombery","year":"2019","journal-title":"Cancer Discov."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"7836","DOI":"10.1021\/acs.jmedchem.4c00027","article-title":"Discovery of the Clinical Candidate Sonrotoclax (BGB-11417), a Highly Potent and Selective Inhibitor for Both WT and G101V Mutant Bcl-2","volume":"67","author":"Guo","year":"2024","journal-title":"J. Med. Chem."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1182\/blood.2023019706","article-title":"Sonrotoclax overcomes BCL2 G101V mutation-induced venetoclax resistance in preclinical models of hematologic malignancy","volume":"143","author":"Liu","year":"2024","journal-title":"Blood"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"5455","DOI":"10.1158\/1078-0432.CCR-21-4037","article-title":"Lisaftoclax (APG-2575) Is a Novel BCL-2 Inhibitor with Robust Antitumor Activity in Preclinical Models of Hematologic Malignancy","volume":"28","author":"Deng","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1158\/1078-0432.CCR-22-3321","article-title":"Novel BCL-2 Inhibitor Lisaftoclax in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematologic Malignancies: First-in-Human Open-Label Trial","volume":"29","author":"Ailawadhi","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"e216785f","DOI":"10.1097\/01.HS9.0000969448.21678.5f","article-title":"P636: A First-in-Human Phase 1 Study of Oral Loxo-338, A Selective BCL2 Inhibitor, in Patients with Advanced Hematologic Malignancies","volume":"7","author":"Kwiatek","year":"2023","journal-title":"HemaSphere"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"2934","DOI":"10.1038\/s41375-020-0846-5","article-title":"Survey of ex vivo drug combination effects in chronic lymphocytic leukemia reveals synergistic drug effects and genetic dependencies","volume":"34","author":"Lukas","year":"2020","journal-title":"Leukemia"},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Wi\u015bniewski, K., and Pu\u0142a, B. (2024). A Review of Resistance Mechanisms to Bruton\u2019s Kinase Inhibitors in Chronic Lymphocytic Leukemia. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25105246"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1038\/leu.2017.32","article-title":"Bruton\u2019s tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia","volume":"31","author":"Deng","year":"2017","journal-title":"Leukemia"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"3705","DOI":"10.1158\/1078-0432.CCR-14-2809","article-title":"Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia","volume":"21","author":"Lamothe","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/s41408-021-00429-z","article-title":"Ibrutinib and venetoclax target distinct subpopulations of CLL cells: Implication for residual disease eradication","volume":"11","author":"Lu","year":"2021","journal-title":"Blood Cancer J."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1182\/blood-2011-10-386417","article-title":"The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo","volume":"119","author":"Ponader","year":"2012","journal-title":"Blood"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"3286","DOI":"10.1182\/blood-2014-02-548610","article-title":"Ibrutinib inhibits BCR and NF-\u03baB signaling and reduces tumor proliferation in tissue-resident cells of patients with CLL","volume":"123","author":"Herman","year":"2014","journal-title":"Blood"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1038\/s41418-020-00692-w","article-title":"Regulation of Bcl-XL by non-canonical NF-\u03baB in the context of CD40-induced drug resistance in CLL","volume":"28","author":"Haselager","year":"2021","journal-title":"Cell Death Differ."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1038\/s41375-023-01898-w","article-title":"Ibrutinib sensitizes CLL cells to venetoclax by interrupting TLR9-induced CD40 upregulation and protein translation","volume":"37","author":"Kielbassa","year":"2023","journal-title":"Leukemia"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1111\/bjh.13149","article-title":"Combination of ibrutinib with ABT-199: Synergistic effects on proliferation inhibition and apoptosis in mantle cell lymphoma cells through perturbation of BTK, AKT and BCL2 pathways","volume":"168","author":"Zhao","year":"2015","journal-title":"Br. J. Haematol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1182\/blood-2019-131732","article-title":"Combined Ibrutinib and Venetoclax in Patients with Relapsed\/Refractory (R\/R) Chronic Lymphocytic Leukemia (CLL)","volume":"134","author":"Jain","year":"2019","journal-title":"Blood"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1001\/jamaoncol.2021.1649","article-title":"Ibrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia: A Nonrandomized Phase 2 Trial","volume":"7","author":"Jain","year":"2021","journal-title":"JAMA Oncol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"4635","DOI":"10.1182\/blood-2023-189711","article-title":"Combined Ibrutinib and Venetoclax for First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL): 5-Year Follow-up Data","volume":"142","author":"Jain","year":"2023","journal-title":"Blood"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"3853","DOI":"10.1200\/JCO.21.00807","article-title":"Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study","volume":"39","author":"Wierda","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1182\/blood.2021014488","article-title":"Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: Primary analysis of the CAPTIVATE FD cohort","volume":"139","author":"Tam","year":"2022","journal-title":"Blood"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"7009","DOI":"10.1200\/JCO.2024.42.16_suppl.7009","article-title":"Outcomes in high-risk subgroups after fixed-duration ibrutinib + venetoclax for chronic lymphocytic leukemia (CLL)\/small lymphocytic lymphoma (SLL): Up to 5.5 years of follow-up in the phase 2 CAPTIVATE study","volume":"42","author":"Wierda","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"EVIDoa2200006","DOI":"10.1056\/EVIDoa2200006","article-title":"Fixed-Duration Ibrutinib-Venetoclax in Patients with Chronic Lymphocytic Leukemia and Comorbidities","volume":"1","author":"Kater","year":"2022","journal-title":"NEJM Evid."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/S1470-2045(23)00452-7","article-title":"Fixed-duration ibrutinib-venetoclax versus chlorambucil-obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial","volume":"24","author":"Niemann","year":"2023","journal-title":"Lancet Oncol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1182\/blood-2024-203269","article-title":"First-Line Ibrutinib Plus Venetoclax Vs Chlorambucil Plus Obinutuzumab in Elderly or Comorbid Patients (Pts) with Chronic Lymphocytic Leukemia (CLL): Glow Study 64-Month Follow-up (FU) and Adverse Event (AE)-Free Progression-Free Survival (PFS) Analysis","volume":"144","author":"Niemann","year":"2024","journal-title":"Blood"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"2722","DOI":"10.1200\/JCO.19.00894","article-title":"Ibrutinib Plus Venetoclax in Relapsed\/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study","volume":"37","author":"Hillmen","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1182\/blood-2022-166700","article-title":"MRD4 Eradication at 6 Months and Early Clearance of MRD with Combination of Ibrutinib Plus Venetoclax Results in Sustained Clinical and MRD Responses: Exploratory Analysis of the Blood Cancer UK TAP Clarity Study","volume":"140","author":"Munir","year":"2022","journal-title":"Blood"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1182\/blood-2020-136960","article-title":"Continued Long Term Responses to Ibrutinib + Venetoclax Treatment for Relapsed\/Refractory CLL in the Blood Cancer UK TAP Clarity Trial","volume":"136","author":"Hillmen","year":"2020","journal-title":"Blood"},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Adalgisa Condoluci, K.P., St\u00fcssi, G., M\u00fcller, G., Dietrich, D., Cantoni, N., Cathomas, R., Mey, U., Widmer, A., Zenz, T., and Gregor, M. (2025). Ibrutinib Lead-In Followed by Venetoclax Plus Ibrutinib Inpatients with Relapsed\/Refractory Chronic Lymphocytic Leukemia. EHA2024, Elsevier.","DOI":"10.1182\/blood.2024026879"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1056\/NEJMoa2310063","article-title":"Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease","volume":"390","author":"Munir","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_92","unstructured":"(2025, January 31). Fixed-Duration Calquence Plus Venetoclax Demonstrated Superior Progression-Free Survival vs. Standard of Care in Previously Untreated Chronic Lymphocytic Leukaemia, with 77% of Patients Progression Free at Three Years in AMPLIFY Phase III Trial. Available online: https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2024\/fixed-duration-calquence-plus-venetoclax-demonstrated-superior-pfs-vs-standard-care-previously-untreated-cll-with-77-of-patients-progression-free-3-years-amplify-phase-iii-trial.html."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1182\/blood.2023022730","article-title":"Acalabrutinib, venetoclax, and obinutuzumab in relapsed\/refractory CLL: Final efficacy and ctDNA analysis of the CLL2-BAAG trial","volume":"144","author":"Giza","year":"2024","journal-title":"Blood"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1200\/JCO-24-02503","article-title":"Phase II Study of Acalabrutinib, Venetoclax, and Obinutuzumab in a Treatment-Na\u00efve Chronic Lymphocytic Leukemia Population Enriched for High-Risk Disease","volume":"43","author":"Davids","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1182\/blood-2021-144336","article-title":"Zanubrutinib in Combination with Venetoclax for Patients with Treatment-Na\u00efve (TN) Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) with del(17p): Early Results from Arm D of the SEQUOIA (BGB-3111-304) Trial","volume":"138","author":"Tedeschi","year":"2021","journal-title":"Blood"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"e879","DOI":"10.1016\/S2352-3026(21)00307-0","article-title":"Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: A multicentre, single-arm, phase 2 trial","volume":"8","author":"Soumerai","year":"2021","journal-title":"Lancet Haematol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1182\/blood.2024024510","article-title":"Fixed-duration pirtobrutinib plus venetoclax with or without rituximab in relapsed\/refractory CLL: The phase 1b BRUIN trial","volume":"144","author":"Roeker","year":"2024","journal-title":"Blood"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1182\/blood-2023-179541","article-title":"Combination Treatment with Sonrotoclax (BGB-11417), a Second-Generation BCL2 Inhibitor, and Zanubrutinib, a Bruton Tyrosine Kinase (BTK) Inhibitor, Is Well Tolerated and Achieves Deep Responses in Patients with Treatment-Na\u00efve Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma (TN-CLL\/SLL): Data from an Ongoing Phase 1\/2 Study","volume":"142","author":"Tam","year":"2023","journal-title":"Blood"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"4614","DOI":"10.1182\/blood-2024-207408","article-title":"Lisaftoclax (APG-2575) Demonstrates Activity and Safety When Given with Accelerated Ramp-up and then Combined with Acalabrutinib or Rituximab in Patients (pts) with Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma (CLL\/SLL), Including Those with Prior Exposure to Venetoclax","volume":"144","author":"Davids","year":"2024","journal-title":"Blood"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"e307","DOI":"10.3324\/haematol.2018.214759","article-title":"The Bruton tyrosine kinase inhibitor zanubrutinib (BGB-3111) demonstrated synergies with other anti-lymphoma targeted agents","volume":"104","author":"Chiara","year":"2019","journal-title":"Haematologica"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"3285","DOI":"10.1182\/blood-2023-174465","article-title":"Zanubrutinib and Venetoclax As Initial Therapy for CLL\/SLL with Obinutuzumab Triplet Consolidation in Patients with Minimal Residual Disease Positivity (BruVenG)","volume":"142","author":"Allan","year":"2023","journal-title":"Blood"},{"key":"ref_102","doi-asserted-by":"crossref","unstructured":"Griffin, J., Wu, Y., Mu, Q., Li, X., and Ho, R.J.Y. (2023). Design and Characterization of a Novel Venetoclax-Zanubrutinib Nano-Combination for Enhancing Leukemic Cell Uptake and Long-Acting Plasma Exposure. Pharmaceutics, 15.","DOI":"10.3390\/pharmaceutics15031016"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"5513","DOI":"10.1007\/s00432-022-04473-5","article-title":"Orelabrutinib and venetoclax synergistically induce cell death in double-hit lymphoma by interfering with the crosstalk between the PI3K\/AKT and p38\/MAPK signaling","volume":"149","author":"Pan","year":"2023","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1182\/blood-2024-211454","article-title":"Combined Pirtobrutinib, Venetoclax, and Obinutuzumab As First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL)","volume":"144","author":"Jain","year":"2024","journal-title":"Blood"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1186\/s13045-022-01386-1","article-title":"Preclinical evaluation of combination nemtabrutinib and venetoclax in chronic lymphocytic leukemia","volume":"15","author":"Muhowski","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1182\/blood-2022-169662","article-title":"A Phase 1 Study with the Novel B-Cell Lymphoma 2 (Bcl-2) Inhibitor Bgb-11417 As Monotherapy or in Combination with Zanubrutinib (ZANU) in Patients (Pts) with CLL\/SLL: Preliminary Data","volume":"140","author":"Cheah","year":"2022","journal-title":"Blood"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"9325","DOI":"10.1182\/blood-2022-169664","article-title":"A Phase 1 Study with the Novel B-Cell Lymphoma 2 (Bcl-2) Inhibitor Bgb-11417 As Monotherapy or in Combination with Zanubrutinib (ZANU) in Patients (Pts) with Non-Hodgkin Lymphoma (NHL) or Waldenstr\u00f6m Macroglobulinemia (WM): Preliminary Data","volume":"140","author":"Soumerai","year":"2022","journal-title":"Blood"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"7078","DOI":"10.1200\/JCO.2024.42.16_suppl.7078","article-title":"Updated efficacy and safety results of BCL-2 inhibitor lisaftoclax (APG-2575) alone or combined with ibrutinib or rituximab in patients (pts) with Waldenstr\u00f6m macroglobulinemia (WM)","volume":"42","author":"Lasica","year":"2024","journal-title":"J. Clin. Oncol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/7\/3193\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:05:33Z","timestamp":1760029533000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/7\/3193"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,29]]},"references-count":108,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,4]]}},"alternative-id":["ijms26073193"],"URL":"https:\/\/doi.org\/10.3390\/ijms26073193","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,29]]}}}